The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

May. 08, 2020
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Xi-Tao Wang, Wellesley, MA (US);

Olufemi A. Adelakun, Kendall Park, NJ (US);

Anne C. Lewin, Lawrenceville, NJ (US);

Alan J. Korman, Piedmont, CA (US);

Mark J. Selby, San Francisco, CA (US);

Changyu Wang, Union City, CA (US);

Haichun Huang, Fremont, CA (US);

Karla A. Henning, Milpitas, CA (US);

Nils Lonberg, Woodside, CA (US);

Mohan Srinivasan, Cupertino, CA (US);

Michelle Minhua Han, Piedmont, CA (US);

Guodong Chen, East Brunswick, NJ (US);

Richard Y. Huang, Bridgewater, NJ (US);

Indrani Chakraborty, Fremont, CA (US);

Susan Chien-Szu Wong, Fremont, CA (US);

Huiming Li, Lexington, MA (US);

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/566 (2006.01); G01N 33/574 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); G01N 33/566 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/7051 (2013.01); G01N 2333/70578 (2013.01); G01N 2333/7151 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7028 (2013.01);
Abstract

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.


Find Patent Forward Citations

Loading…